In this study, we found that BRG1 deficiency promoted the progression of DCM and aggravated cardiac dysfunction in vivo, demonstrating that BRG1 is a potential therapeutic target of DCM. The gene discussed is SMARCA4; the disease is familial dilated cardiomyopathy.